3.5.6. erythrocytosis. elevated haematocrit level common adverse effect testosterone therapy. stimulation erythropoiesis normal biological action enhances delivery oxygen testosterone-sensitive tissues (e.g., striated, smooth cardiac muscle). elevation normal range haematocrit usually becomes evident three twelve months testosterone therapy initiation. however, polycythaemia also occur subsequent increase testosterone dose, switching topical parenteral administration and, development comorbidity, linked increase haematocrit (e.g., respiratory haematological diseases). evidence increase haematocrit including 54% causes adverse effects. haematocrit exceeds 54% testosterone independent, weak associated rise cv events mortality [79,177-179]. relationship complex studies based patients cause secondary polycythaemia, included smoking respiratory diseases. specific studies men testosterone-induced erythrocytosis. detailed, traverse study, included symptomatic hypogonadal men aged 45-80 years pre-existing high risk cvd, showed mild higher incidence pulmonary embolism, component adjudicated tertiary end point venous thromboembolic events, testosterone therapy placebo group (0.9% vs. 0.5%) . however, three previous large studies shown evidence testosterone therapy associated increased risk venous thromboembolism . those, one study showed increased risk peaked six months initiation testosterone therapy, declined subsequent period . one study venous thromboembolism reported 42 cases 40 diagnosis underlying congenital thrombophilia (including factor v leiden deficiency, prothrombin mutations homocysteinuria) . meta-analysis rcts testosterone therapy reported venous thromboembolism frequently related underlying undiagnosed thrombophilia-hypofibrinolysis disorders . rct testosterone therapy men chronic stable angina adverse effects coagulation, assessment tissue plasminogen activator plasminogen activator inhibitor-1 enzyme activity fibrinogen levels . similary, another meta-analysis systematic review rcts found testosterone therapy associated increased risk venous thromboembolism . testosterone therapy elevated haematocrit levels likely occur baseline level toward upper limit normal prior initiation. added risks raised haematocrit testosterone therapy include smoking respiratory conditions baseline. higher haematocrit common parenteral rather topical formulations. accordingly, large retrospective two-arm open registry, comparing effects long-acting testosterone undecanoate testosterone gels showed former preparation associated higher risk haematocrit levels > 50%, compared testosterone gels . men pre-existing cvd extra caution advised definitive diagnosis hypogonadism initiating testosterone therapy monitoring testosterone well haematocrit treatment. elevated haematocrit absence comorbidity acute cv venous thromboembolism managed reduction testosterone dose, change formulation elevated haematocrit high venesection (500 ml), even repeated necessary, usually need stop testosterone therapy.